Tandem Diabetes Care's top-line growth hasn't been great over the past few years. If it can successfully address challenges detrimental to revenue growth, it may become an attractive stock -- even ...

Wondering if Tandem Diabetes Care at around $21 a share is a hidden bargain or a value trap? You are not alone, and that is exactly what we are going to unpack here. The stock has bounced 2.2% over ...

About Tandem Diabetes Care Inc. Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.